anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a Ge adsorbent which is useful for a 68Ge-68Ga generator system. Specifically disclosed is a Ge adsorbent comprising an organic synthetic resin having a glucamine group. Preferably, the organic synthetic resin is a polymer produced by introducing an N-methylglucamine into a (glycidyl methacrylate)-(ethylene glycol dimethacrylate) copolymer. Alternatively, the organic synthetic resin may be a polymer produced by introducing an N-methylglucamine into a styrene-divinylbenzene copolymer. A column filled with the polymer can adsorb Ge well and can desorb Ga readily, and therefore can collect 68Ga produced from 68Ge with high efficiency. Therefore, the polymer can be used as an excellent adsorbent for use in a 68Ge-68Ga generator system.
The study employs an open-label "active switch" design that moves subjects from infliximab to golimumab 2 mg/kg IV. In general, subjects eligible for the study include men or women who are currently receiving infliximab in actual clinical practice who are at least 18 years of age with active rheumatoid arthritis, and have previously demonstrated initial and/or temporary improvement in disease signs and symptoms, but now exhibit a diminished response and inadequate disease control despite continued treatment. Subjects must have received infliximab in combination with methotrexate for a minimum of 9 months prior to the first screening visit.

The screening visit will occur sometime between Week -12 and Week -10. Consenting subjects who meet screening criteria will receive their final dose of infliximab at Week -8 as part of actual clinical practice. Golimumab IV treatment, which will be supplied by the sponsor, will be received at Weeks 0, 4, 12, 20, and 28. The primary endpoint is at Week 24, the final efficacy assessment is at Week 32, and a follow-up safety assessment by telephone is at Week 44. There will be a maximum of 36 weeks between the last infliximab infusion at Week -8 and the last infusion of golimumab at Week 28. The duration of study participation is expected to be a maximum of 56 weeks (including the Screening Period, 32 weeks of golimumab treatment and assessment, and a 12-week safety follow-up).
Focus groups contain 5-7 patients. Groups will be stratified according to socio-economic levels and according to treatment (radical prostatectomy with conservation or without preservation of the neuro vascular strips).
Orthostatic hypotension (OH) is a form of orthostatic intolerance (OI) and a key physiological indicator of autonomic dysfunction that is associated with an increased risk of major cerebrocardiovascular events. Symptoms of cerebral hypoperfusion have been reported in patients with OH, which worsens symptoms and increases the risk of syncope. Since pharmacological interventions increase blood pressure (BP) independent of posture and do not restore normal baroreflex control, nonpharmacological treatments are considered the foundation of OH management. While reductions in cerebral blood flow velocity (CBFv) during orthostatic stress are associated with a decrease in end-tidal CO2 (EtCO2) and hypocapnia in patients with OI, their contribution to the severity of OH is not well understood. These measures have been physiological targets in a wide variety of biofeedback interventions. This study explored the relationship between cardiovascular autonomic control, EtCO2 and cerebral hypoperfusion in patients (N = 72) referred for OI. Patients with systolic OH were more likely to be male, older, demonstrate reduced adrenal and vagal baroreflex sensitivity, and reduced cardiovagal control during head-up tilt (HUT) than patients without systolic OH. Greater reduction in CBFv during HUT was associated with a larger reduction in ETCO2 and systolic BP during HUT. While deficits in cardiovascular autonomic control played a more important role in systolic OH, reduced EtCO2 was a major contributor to orthostatic cerebral hypoperfusion. These findings suggest that biofeedback treatments targeting both the autonomic nervous system and EtCO2 should be part of nonpharmacological interventions complementing the standard of care in OH patients with symptoms of cerebral hypoperfusion.
Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
The family consultation will be one, 1-hour session conducted by trained, master's level therapists. The goals of the meetings are: a) Review patient and family understanding of events that caused the hospital admission; b) increase family awareness of the level of cognitive impairment that the patient is experiencing; c) discuss ways the family can get involved and help the patient with their medication and dialysis adherence; d) use motivational interviewing techniques as needed. This will be provided in addition to the usual care that inpatients receive in this unit.
The experimental group will receive the Appetite to Play + intervention which is a capacity-building intervention that support childcare providers in implementing the best practices for active play. It includes a 3 e-learning online modules and then the are supported with weekly . bi-weekly emails.
The third group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last.
All participants diagnosed with relapsed/refractory (R/R) cHL, CTCL (mycosis fungoides \[MF\] and cutaneous anaplastic large cell lymphoma \[pcALCL\]) and sALCL with CD30 positive, and who have previously achieved a CR or PR with BV treatment and subsequently experienced disease progression/relapse and were administered BV retreatment will be observed retrospectively from their initiation of BV treatment until participant's inclusion date in the study or until treatment discontinuation due to toxicities or any cause. All study data will be collected retrospectively from the medical records.
An apparatus can detect surgical instruments provided with RFID transponders. The apparatus has a receiving space delimited by a bottom and side walls. A surgical instrument can be introduced into the receiving space through an upper side of the receiving space. The receiving space is shielded from external electromagnetic waves at the bottom and at the sides by shielding. An antenna device is configured within the shielding in at least two side walls that extend transversely to one another and/or parallel to one another, in such a way that the antenna device can transmit electromagnetic waves into the receiving space and receive electromagnetic waves from the receiving space with respect to two different sides of the receiving space. An identification device is configured to identify a surgical instrument introduced into the receiving space and store identification data corresponding to the identification of the surgical instrument.
PURPOSE:To obtain a melanogenesis-suppressing external agent containing a liquid obtained by culturing yeast in a sugar syrup or a cultured extract, exhibiting remarkably excellent melanogenesis-suppressing effect and humectant effect and useful also as an active component for skin-beautifying cosmetic required to give moist feeling to the skin. CONSTITUTION:A yeast belonging to the genus Saccharomyces is cultured in a sugar syrup (especially a medium derived from barley) and the obtained cultured yeast liquid or extract of the cultured liquid is used as an active component for the objective melanogenesis-suppressing external agent. The sugar syrup to be used as a medium is preferably produced by heating and dilating barley, wheat, rye, oat, etc., optionally in the presence of water and treating the product with saccharifying enzyme to increase the production of the melanogenesis-suppressing substance by yeast. Saccharification is performed in high efficiency by adding an alpha-amylase in combination with a glucoamylase as the saccharification enzymes. The amount of the cultured liquid or culture extract in the preparation is preferably 0.1-10wt.%. The external agent can be used in the form of poultice, plaster, paste, cream, ointment, aerosol, sun-care, bath-salt, soap, etc.
The invention relates to a food processing technology, which in particular relates to a preparation method for a pulpiness pumpkin juice. The picked fresh pumpkin without insect damage is cleaned in the fresh water, and then is dispersed into granules with diameter of 1-5mm after being bisected and deseeded adding fluid infusion at the same time. Then the pumpkin granules are pre-cooked for 30s-8min. under the temperature of 80 to 100 DEG C till the granules are done to a turn. Then the done pumpkin is cooled to 60 to 80 DEG C for 2-4min. and then is beaten, centrifuged, prepared, degasified, isotroped, sterilized and canned to get the pumpkin juice. By adopting the preparation technology of the invention, the juice extraction rate of the pumpkin and the extraction rate of the nutrition element can be raised and the color and luster of the pumpkin is also improved at the same time. The decortication rate is up to above 98 percent to lighten the labor burden, improve the work effect and achieve the continuous production.
Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
Methods for treating a connective tissue disorder by introducing at least one gene encoding a product into at least one target cell of a mammalian host for use in treating the mammalian host are disclosed. These methods include employing recombinant techniques to produce a vector molecule containing the DNA sequence encoding for the product and infecting the target cell of the mammalian host using the vector. The injection can be done in vivo, by directly injecting the vector into the host, or can be done in vitro by transfecting a population of cultured target cells with the vector and transplanting them each into the host. Nonviral means can also be used to introduce the DNA sequence to the host. Administration of more than one gene of interest results in an enhanced therapeutic benefit.  
     Also disclosed is a method for treating a connective tissue disorder by introducing at least one gene encoding a product into at least one target cell of a joint of a host for use in treating multiple joints of the host. Injection of a vector molecule containing the DNA sequence encoding for a product of interest, or non-viral introduction of such a DNA sequence, to one joint of a mammalian host results in a therapeutic benefit in that joint as well as other joints in the host.
Intracranial electrical stimulation (iES) of auditory cortex can elicit sound experiences with a variety of perceived contents (hallucination or illusion) and locations (contralateral or bilateral side), independent of actual acoustic inputs. However, the neural mechanisms underlying this elicitation heterogeneity remain undiscovered. Here, we collected subjective reports following iES at 3062 intracranial sites in 28 patients (both sexes) and identified 113 auditory cortical sites with iES-elicited sound experiences. We then decomposed the sound-induced intracranial electroencephalogram (iEEG) signals recorded from all 113 sites into time-frequency features. We found that the iES-elicited perceived contents can be predicted by the early high-γ features extracted from sound-induced iEEG. In contrast, the perceived locations elicited by stimulating hallucination sites and illusion sites are determined by the late high-γ and long-lasting α features, respectively. Our study unveils the crucial neural signatures of iES-elicited sound experiences in human and presents a new strategy to hearing restoration for individuals suffering from deafness.
Disinfectant contg. complex bonded I2 is prepd. by I2-treatment of a hydrophilic organic carrier, (I), which forms a 3-dimensional network kept together by covalent bonds, which is insoluble in water but capable of a gel and pref. has swelling capacity, in water, of 2-100 ml/g i.e. 1 g dry (I) forms a gel having vol. 2-100 ml when completely swollen in water. I2-treatment of (I) pref. takes place at =50 (esp. 15-40) degrees C, in the presence of a liquid reaction medium, esp. water, which is capable of swelling (I). Powdered iodophors can be used for spray-disinfection of large surfaces. In water, iodophors can be used for disinfecting swimming pools, cooling towers, equipment in contact with milk, wine or beer. Iodophors can also be used for ion-exchanger or molecular sieve operations with simultaneous disinfection of material. Iodophors can be used also as anti-microbial components in chemical-technical, cosmetic and medicinal compsns., e.g. as powders, deodorants, ointments or creams, for disinfecting skin and wounds, and for preventing hospital infection.
Schizophrenia is a very stubborn and painful mental disease, and the quantity of patents is large. Schizophrenia control medicines are clinically used at present, the pharmacological mechanism of the schizophrenia control medicines is characterized in that the motion of center dopamine is controlled through obstruction in order to control schizophrenia, and the schizophrenia control medicines have severe side effects. Schizophrenia treatment medicines are invented in the invention, and can treat and control schizophrenia in a dopamine normal motion grooming mode. The raw materials of the schizophrenia treatment medicines are obtained through extraction separation of plants, and undergo a two-step chemical reaction to obtain alkaloid compounds, the alkaloid compounds are separated through a chiral separating column to obtain chiral compounds, and the chiral compounds are processed to prepare the new medicines. Biological determination experiments prove that molecules of the medicines can dredge dopamine protection molecule channels to promote normal running of a dopamine function system in the system. Mouse animal test confirms that the medicines disclosed in the invention can treat schizophrenia and are safe and effective.
The invention provides a photodynamic bactericidal polymer and a preparation method and application thereof. The polymer consists of a main chain and a side chain, wherein the side chain consists of a long alkyl chain with quaternized terminal, can be combined with the surface of bacteria with negative charges to form a compact assembly, so that the bacterial membrane is permeable; the main chain is composed of benzene, fluorene and thiophene, has a strong rigid structure, and can generate active oxygen by being excited and sensitized by light under the condition of illumination, so that the efficient sterilization effect is achieved. The polymer can be used as an antibacterial agent, can kill gram-positive and gram-negative bacteria, can kill fungi, and has broad-spectrum antibacterial function. The polymer has the advantages of simple preparation, mild reaction and higher yield. The polymer is used as an efficient photodynamic antibacterial material, the concentration required by sterilization is low, the light dose is small, and the efficient sterilization effect can be achieved by common white light irradiation. The polymer of the invention emits fluorescence in a long wave region and can also be used for biological fluorescence imaging.
Pig bile- and Fructus Evodiae sauce-processed Rhizoma Coptidis (Danhuanglian, DHL; Yuhuanglian, YHL, respectively) are two types of processed Rhizoma Coptidis (Huanglian, HL) in traditional Chinese medicine (TCM). DHL and YHL are representative of HL generated from the subordinate and counter system processing methods, respectively, both noted for their anti-inflammatory effects. How these processing methods can affect the medicinal efficacy of HL remains a hot topic. Here, we discussed the influence of the two methods on the efficacy of final HL products (i.e., DHL and YHL) by comparing their components and anti-inflammatory mechanisms. Enzyme-linked immunosorbent assay was employed to measure inflammatory factors in RAW264.7 cells induced by lipopolysaccharide, and UPLC-Q-Exactive Orbitrap-MS was utilized to analyze the endogenous differential metabolites of RAW264.7 cells treated with HL, YHL, and DHL, and thus to identify the related metabolic pathways. Finally, using network pharmacology, we constructed a "disease-target-differential metabolites-active ingredients" network map. Compared with the control, all three products, HL, YHL, and DHL, significantly reduced IL-6, TNF-α, and IL-1β levels. 12 differential metabolites related to inflammation were identified and 25 target proteins were overlapping among the three groups. Notably, the anti-inflammatory effects of DHL and YHL were mediated by metabolic pathways such as aminoacyl-tRNA biosynthesis, arginine and proline metabolism, alanine, aspartate and glutamate metabolism, and arginine biosynthesis. Specifically, DHL significantly impacted free fatty acid levels, which was not observed with HL and YHL. On screening, DHL had 9 active ingredients, including three from pig bile, and YHL had 12 active ingredients, with six from the processing excipient Fructus Evodiae. The distinct anti-inflammatory mechanisms and material basis of YHL and DHL were characterized by consistency and distinctiveness. Thus, this study underscores the significant influence of processing methods on the medicinal efficacy of TCMs by revealing their regulatory mechanisms and material bases.
In addition to residual tumor cells, surgery-induced inflammation significantly contributes to tumor recurrence and metastasis by recruiting polymorphonuclear neutrophils (PMNs) and promoting their involvement in tumor cell proliferation, invasion and immune evasion. Efficiently eliminating residual tumor cells while concurrently intervening in PMN function represents a promising approach for enhanced postoperative cancer treatment. Here, a chitosan/polyethylene oxide electrospun fibrous scaffold co-delivering celecoxib (CEL) and doxorubicin-loaded tumor cell-derived microparticles (DOX-MPs) is developed for postoperative in-situ treatment in breast cancer. This implant (CEL/DOX-MPs@CP) ensures prolonged drug retention and sustained release within the surgical tumor cavity. The released DOX-MPs effectively eliminate residual tumor cells, while the released CEL inhibits the function of inflammatory PMNs, suppressing their promotion of residual tumor cell proliferation, migration and invasion, as well as remodeling the tumor immune microenvironment. Importantly, the strategy is closely associated with interference in neutrophil extracellular trap (NET) released from inflammatory PMNs, leading to a substantial reduction in postoperative tumor recurrence and metastasis. Our results demonstrate that CEL/DOX-MPs@CP holds great promise as an implant to enhance the prognosis of breast cancer patients following surgery.
S-adenosylhomocysteine hydrolase (AHCY) hydrolyzes S-adenosylhomocysteine to adenosine and L-homocysteine, and is well known as a potential therapeutic target for cancer, malaria, or viral diseases. The present invention has confirmed a molecular mechanism of the AHCY for breast cancer. The role of the AHCY in the proliferation and metastasis of breast cancer has been evaluated by using a stable cell line through an XTT analysis, a wound healing analysis and a transwell assay analysis. Thereby, it is determined that the AHCY controls an ERK cell signaling pathway and thereby is involved in a malignant effect and a cell cycle of breast cancer cells. In order to further evaluate the role of the AHCY in vivo, a growth of a mammary gland in an AHCY knockout mouse has been observed by dyeing the mammary gland, and as a result, it is confirmed that the growth of the mammary gland is affected by an AHCY deficiency. In summary, the present invention has revealed that the AHCY is involved in the proliferation and metastasis of breast cancer by means of an ERK cell signaling path.
It has been shown that excitotoxicity and tau-mediated toxicities are major contributing factors to neuronal death in Alzheimer's disease (AD). The excitatory amino acid transporter 2 (EAAT2 or GLT-1), the major glutamate transporter in the brain that regulates glutamate levels synaptically and extrasynaptically, has been shown to be deficient in AD brains, leading to excitotoxicity and subsequent cell death. Similarly, buildup of neurofibrillary tangles, which consist of hyperphosphorylated tau protein, correlates with cognitive decline and neuronal atrophy in AD. However, common genes and pathways that are critical in the aforementioned toxicities have not been well elucidated. To investigate the impact of glutamate dyshomeostasis and tau accumulation on translational profiles of affected hippocampal neurons, we used mouse models of excitotoxicity and tau-mediated toxicities (GLT-1-/- and P301S, respectively) in conjunction with BAC-TRAP technology. Our data show that GLT-1 deficiency in CA3 pyramidal neurons leads to translational signatures characterized by dysregulation of pathways associated with synaptic plasticity and neuronal survival, while the P301S mutation induces changes in endocytic pathways and mitochondrial dysfunction. Finally, the commonly dysregulated pathways include impaired ion homeostasis and metabolic pathways. These common pathways may shed light on potential therapeutic targets for ameliorating glutamate and tau-mediated toxicities in AD.
Patients receive guadecitabine SC or ASTX727 PO on days 1-5. Patients also receive belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood during screening, tumor biopsy during screening and on study, and MRI or CT throughout the trial.
Participants were advised with a hypocaloric diet with the following composition: 20% protein, 30% fat and 50% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.